Abstract -, 1tObjective-To study the effect of salmon calcitonin (salcatonin) given intranasally on calcium and bone metabolism in early postmenopausal women. Design-Double blind, placebo controlled, randomised group comparison.
Introduction
Oestrogen is generally accepted as effective prophylaxis against postmenopausal bone loss'2 and osteoporosis." This effect may be mediated partly by calcitonin as women receiving treatment with oestrogen have raised plasma calcitonin concentrations.5'6 Not all studies, however, have found a relation between calcitonin and oestrogen. ' Calcitonin, a peptide hormone produced in the parafollicular cells of the thyroid, is implicated in calcium homoeostasis by inhibiting bone resorption through a direct action on osteoclasts.9 It has therefore been used to treat diseases of calcium metabolism that are characterised by increased turnover of bone, such as Paget's disease and osteoporosis. ' Calcitonin has until recently been available only as an injection, but a nasal spray has now been developed. We showed recently that salmon calcitonin (salcatonin) given intranasally is effective in treating established postmenopausal osteoporosis." The rate of bone loss, however, is much faster during the early postmenopausal years. The question is, therefore, whether salcatonin is a valuable alternative to oestrogen in prophylaxis against postmenopausal osteoporosis. Results of preliminary studies indicate that salcatonin given both intranasally and by injection prevents early postmenopausal bone loss in the lumbar spine.'2 1"
The aim of the present double blind, placebo controlled study was to examine the long term effect of salcatonin given intranasally on early postmenopausal bone loss in the spine, the forearm, and the total skeleton.
Methods

DESIGN OF STUDY
The study comprised 52 women aged 47-56 who had had a natural menopause two and a half to five years previously. The selection procedure, described in detail elsewhere, ' Figure 1 shows the mean changes in spinal bone mineral content during the study. In women receiving salcatonin bone mineral content increased by 2-5%, whereas in women receiving placebo it declined by 5-7% (p<0-001). Spinal bone mineral content was higher in those receiving salcatonin than in those receiving placebo both after one year (p<0-05) and after two years (p<0-001): after one year the difference was 3-8% (95% confidence interval 0-0 to 7-6%) and after two years it was 8-2% (3-8 to 12-6%).
The mean bone mineral content in the forearms (distal and proximal) and total skeleton of both women receiving salcatonin and those receiving placebo decreased by about 2% a year (fig 2) . After two years there were no significant differences in bone mineral content between the two groups at these sites. Figure 3 shows the mean changes in the biochemical indicators of bone formation and bone resorptionnamely, serum alkaline phosphatase activity, plasma bone Gla protein concentration and fasting urinary calcium and hydroxyproline concentrations corrected for excretion of creatinine. There were no significant differences between the women receiving salcatonin and those receiving placebo in the changes in any of these four variables. variables-that is, blood pressure, serum creatinine concentration, serum aspartate aminotransferase activity, haemoglobin concentration, leucocyte count, ratio of calcium to protein concentrations, and fasting blood glucose concentration.
Discussion
The study group was a representative sample of healthy early postmenopausal women. Morphology, bone mass, and biochemical estimates of bone turnover were similar in the women who completed the study and those who did not. The methods used in the study are well established in our laboratory and have precision errors sufficiently low for them to detect clinically relevant changes in calcium metabolism of groups of subjects.4 These facts,'and the double blind, placebo controlled design of the study, validate our results.
We found that 100 IU ofsalcatonin given intranasally had a selective effect by preventing bone loss from the spine but not from the forearms or the total skeleton. Reginster et al also found that salcatonin prevented spinal bone loss, but they did not measure its effect on bone mineral content in other parts of the skeleton. ' 29 however, have shown that bone loss from the spine exceeds that from peripheral bones, at least during the early postmenopausal years. The lumbar spine bears weight, and many women with osteoporosis present with one or more spinal crush fractures; it is therefore of special clinical relevance. But as bone loss affects all parts of the skeleton prevention at all sites is certainly preferable. The selective effect of salcatonin given intranasally on the spine and the lack of a detectable effect on the biochemical indicators of calcium metabolism suggest that the dose of salcatonin may have been too low. Theoretically, a small but undetectable decrease in bone resorption would lead to a slowing down of bone loss. This might particularly be the case in the spine, where the bone turnover and thus the difference between bone formation and bone resorption are high. This suggests that a higher dose would prevent bone loss throughout the skeleton. Other studies have shown an effect of 100 IU of salcatonin given by injection in preventing bone loss at sites other than the spine (the forearm and total body calcium concentration),"0 3 but the bioavailability of salcatonin given intranasally is low: results of a study on the preparation used in the present study showed a bioavailability of about 40%. 32 We conclude that giving 100 IU salcatonin intranasally to healthy early postmenopausal women affects calcium metabolism and prevents bone loss in the spine and that higher doses may have an effect in other parts of the skeleton.
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